BTG Plc announced the appointment of Melanie Lee as a non-executive director, effective immediately.
Dr Lee is chief executive of Syntaxin Ltd, which is developing biopharmaceuticals to control cell secretion. She is also chairman of Cancer Research Technology Ltd, the technology transfer arm of Cancer Research UK.
Her appointment comes at a time when BTG is stepping up its efforts to market products to the hospital market. To further this objective it recently made an agreed bid to acquire Biocompatibles International Plc. Copyright 2010 Evernow Publishing Ltd